J. Goldman & Co’s AstraZeneca AZN Stock Holding History

J. Goldman & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50,000	Closed	-$7.79M	–	463
2024 Q3	$7.79M	Buy	+50,000	New	+$8.07M	0.22%	124
2023 Q4	–	Sell	-61,250	Closed	-$8.3M	–	349
2023 Q3	$8.3M	Sell	61,250 -31,900	-34%	-$4.36M	0.29%	100
2023 Q2	$13.3M	Buy	+93,150	New	+$13.7M	0.48%	63
2022 Q4	–	Sell	-50,000	Closed	-$5.48M	–	375
2022 Q3	$5.48M	Buy	+50,000	New	+$6.34M	0.26%	115

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

J. Goldman & Co's AZN Position: Q4 2022 in Review

J. Goldman & Co sold out of AstraZeneca (AZN) in Q4 2022, closing a stake of 11,510 shares — an estimated $1.26M sold.

J. Goldman & Co first reported a position in AZN in Q2 2014 and held it in 3 quarters. The position peaked at $2.3M in Q2 2014. 1,061 funds tracked by Wall St. Rank hold AZN as of Q4 2022.

J. Goldman & Co reported no remaining AstraZeneca position as of Q4 2022 after selling out during the quarter.
J. Goldman & Co sold 11,510 AstraZeneca shares in Q4 2022, an estimated $1.26M.
J. Goldman & Co first reported a position in AstraZeneca in Q2 2014 and held it in 3 quarters.
J. Goldman & Co's AstraZeneca position peaked at $2.3M in Q2 2014.
1,061 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2022.

Based on J. Goldman & Co's 13F filing for Q4 2022, filed 14 Feb 2023.